Their work, published in a study in Nature magazine, was spearheaded by Penn associate professor of Biology J. Nicholas Betley.
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback